Skip to main content

Drug Interactions between Lets Gel Kit and opicapone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

EPINEPHrine topical opicapone

Applies to: Lets Gel Kit (epinephrine / lidocaine / tetracaine topical) and opicapone

MONITOR: COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.

MANAGEMENT: The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.

References

  1. (2001) "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals
  2. (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals
  3. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A (1995) "The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine." Clin Pharmacol Ther, 58, p. 221-7
  4. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

opicapone food

Applies to: opicapone

ADJUST DOSING INTERVAL: Food may reduce the rate and extent of absorption of opicapone. When opicapone was administered following a moderate fat/moderate calorie meal, mean opicapone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 62% and 31%, respectively, while the time to reach peak concentration (Tmax) was delayed by 4 hours.

MANAGEMENT: Patients should avoid eating 1 to 2 hours before and after taking opicapone.

References

  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2020) "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc.

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer